British Biotech Defends Patent In Gilead's Hep C Fight
Biotech NuCana PLC is fighting a bid by Gilead Sciences to invalidate its patent relating to the treatment of cancer and viral diseases, saying the pharmaceutical giant's hepatitis C drugs infringe...To view the full article, register now.
Already a subscriber? Click here to view full article